Achaogen, an infectious disease therapeutics company, is developing solutions to the problem of drug resistance.

Alexza, a drug delivery company founded by Dr. Alejandro Zaffaroni, is developing a proprietary technology that leverages the pharmacodynamics of existing therapies to rapidly deliver drugs locally and systemically through the lung.

Ambrx, a protein therapeutics company, is exploiting technology developed by Dr. Peter Schultz in the novel field of protein medicinal chemistry to enable the biosynthesis of proteins with new and improved physical, chemical, and pharmacological properties.

Anaphore, is a protein therapeutics company with a mission to create improved biologic-based therapeutics using proprietary established platforms. Anaphore focuses its internal product portfolio on immune-based diseases such as musculoskeletal and autoimmune diseases.

Antipodean is an early-stage clinic ready pharmaceutical company developing treatments for neurodegenerative diseases such as Parkinson's Disease and Friedrich's Ataxia that are associated with mitochondrial dysfunction.

Ikaria is developing products to treat high-risk, critically ill patients by utilizing inducible reversible metabolic hibernation, a technology originally discovered by Mark Roth, PhD.

Ilypsa (acquired by Amgen), a spinout of Symyx Technologies (NASDAQ: SMMX), is leveraging Symyx's existing high-throughput technologies to discover and develop new polymer-based therapeutics.

KaloBios, a monoclonal antibody therapeutics company with a proven development team, is developing proprietary technologies for engineering high-affinity human antibodies.

Kalypsys, a spinout of the Genomics Institute of the Novartis Research Foundation, is leveraging robotics and cellular assay development capabilities for high-throughput screening of compounds for the treatment of oncological and inflammatory diseases.

Marcadia is a biopharmaceutical company developing a portfolio of novel therapeutics for metabolic diseases.

Miikana (acquired by Entremed), a clinically driven oncology company founded out of the former Amgen Institute, is building its portfolio through small molecule discovery programs.

Panomics (formerly Genospectra), a life science reagents company, is developing novel cell-based assays and tools to enable multiplexed measurements of molecular events in a quantitative and scalable manner.

Pearl Therapeutics is developing products for the treatment and prevention of inflammatory, obstructive and allergic conditions in respiratory diseases.

PhaseRx Inc is biopharmaceutical company focused on developing novel approaches to the delivery of siRNA and other macromolecules.  The core delivery platform is based on polymer technology developed in the laboratories of Profs. Pat Stayton and Allan Hoffman at the University of Washington.

Pulmatrix is a pharmaceutical company developing inhalable aerosols and enabling technologies that help control respiratory infectious disease and human-source airborne contamination.

Relypsa, Inc is a biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs. The company’s most advanced therapeutic programs include a novel potassium binder for treatment of hyperkalemia, known as RLY105, as well as a novel sodium binder, RLY102, for the potential treatment of congestive heart failure. Relypsa was spun out following the acquisition of Ilypsa by Amgen.

Semprus BioSciences (formerly SteriCoat Corporation) is a biotechnology company developing medical devices incorporating the first implantable and permanently antimicrobial surface technology. The intellectual property comes from the MIT labs of Prof. Robert Langer and Prof. Greg Stephanopoulos.

Synosia Therapeutics is a drug development company focused on finding innovative treatments for disorders of the central nervous system (CNS).

Variation Biotechnologies is an innovative vaccine company leveraging bioinformatics to develop novel synthetic vaccines against highly variant pathogens.